To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Monika Schäfer-KortingMonika Schäfer-Korting (* May 7, 1952 in Gießen) is a German Pharmacologist and Toxicologist. Additional recommended knowledgeLifeSchäfer-Korting has studied Pharmacy at Johann Wolfgang Goethe University of Frankfurt am Main from 1971 to 1975. In 1976 she was approved as a Pharmacist. In 1977 she obtained the degree of a PhD as a pupil of Prof. Dr. Dr. Ernst Mutschler. In 1989 she obtained her post-doctoral degree (Habilitation). In 1994 she has been appointed as the first Professor and Chairperson for Pharmacology at the Faculty of Pharmacy of Free University of Berlin (FU Berlin). From 2007 onward as already from 1997 to 1999 she has served as a Vice President for Life Sciences and Research of FU Berlin. From 2002 onward she has been the speaker of the DFG-Research group: “Innovative active pharmaceutical ingredients and carrier systems: Integrative optimization for the treatment of inflammatory and hyper-poliferative diseases (FG 463)”. She has coordinated the BMBF-Network project: “Validation study for the testing for skin penetration using biotechnologically produced skin models (FKZ 0312881)“. Schäfer-Korting has been a co-author of the text book on pharmacology and toxicology named „Mutschler. Arzneimittelwirkungen (Drug Actions)“ whose most recent 8th edition has been published in 2001. For Springer Verlag in Heidelberg she serves as the editor of a series of monographs entitled: „Optimized drug therapy“, for the ABW Verlag Berlin she is editing the series of monographs entitled „The Critical Drug Monograph (TCDM)“ She serves as a member of the editorial board of mycoses and Skin Pharmacology and Physiology. She is a member of the board of Gesellschaft für Dermopharmazie (Society for Dermopharmacy) as well as the head of the scientific advisory board of Bundesinstitut für Risikobewertung, Berlin. The characterization of the benefit to risk ratio of drugs is in the focus of her scientific work. In 1999 Schäfer-Korting has published the monograph: “The Benefit/Risk-Ratio: A Handbook of the Rational Use of Potentially Hazardous Drugs“, together with Hans Christian Korting. Topical glucocorticoids with increased benefit to risk ratio such as prednicarbate form a paradigm in the context. Currently, she is particularly interested in signal transduction in various tissues looking for innovative active pharmaceutical ingredients especially for skin disease. Here the focus is on Sphingosine-1-Phosphate (S1P) and the corresponding receptor. In terms of developing new drugs the pro-drug concept is of particular relevance. As early as in the stage of developing new active ingredients also the possibilities of creating adequate formulations is considered. With cutaneous drug treatment liposomes and nano-structured lipidic carriers are considered particularly interesting. To reduce the number of animal experiments in the context of toxicologic investigations animal-sparing types of experimentation are developed using skin models. Since 1980 Professor Dr. Monika Schäfer-Korting has been married with Professor Dr. Hans Christian Korting. Literature
References |
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Monika_Schäfer-Korting". A list of authors is available in Wikipedia. |